drugset / Trial / NCT01462474
Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study of mono famitinib has shown that the drug's toxicity is manageable. PURPOSE: This phase I trial is studying the safety and tolerance of concurrent chemoradiotherapy with famitinib for patients with locally advanced nasopharyngeal carcinoma.
Timeline
- Start
- 2011-10
- Primary completion
- 2015-08
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | 12.5 mg | Oral |
| Subject | Famitinib | Small molecule | 16.5 mg | Oral |
| Subject | Famitinib | Small molecule | 20 mg | Oral |
| Subject | Famitinib | Small molecule | 25 mg | Oral |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |